Abnova Taiwan Corp

Abnova Taiwan Corp maintains a strong liquidity position, with a current ratio of 9.31, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to 302,400,000 TWD, which supports its liquidity and operational flexibility. The debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing.

In terms of profitability, the company's return on equity (ROE) is 0.021, and its return on assets (ROA) is 0.0193. These figures indicate that the company is generating modest returns relative to its equity and total assets. While these returns are below the industry median for biotechnology and medical research firms, they suggest a stable and consistent performance.

The company's revenue is concentrated in the life sciences tools and services segment, as disclosed in its classification and financial data. There is no indication of significant geographic diversification in the provided data, and the company's primary operations appear to be based in Taiwan. This concentration may expose the company to regional economic and regulatory risks.

Looking at the growth trajectory, the company's revenue for the latest period was 85,003,000 TWD. While the company has a positive operating cash flow of 11,427,000 TWD and a free cash flow of 30,059,000 TWD, there is no specific growth rate provided. The company's capital expenditure is negative, indicating that it is not investing in new capital assets at the moment.

The risk assessment indicates that the company has low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags, and the company's capital structure is not expected to change significantly in the near term. The dilution potential is low, and there are no indications of recent or planned share issuances that would dilute existing shareholders.

Recent events, as reflected in the financial data, show that the company has maintained a stable financial position. The latest actual EPS is 0.97 TWD, and the latest actual revenue is 475,073,000 TWD. These figures suggest that the company is meeting or slightly exceeding analyst expectations, although there is no indication of significant growth or volatility in the recent financial results.

Operating and net margins exceed the 75th percentile of the biotechnology cohort, indicating superior profitability relative to peers.

Return on equity significantly outperforms the cohort median, demonstrating efficient capital utilization compared to industry peers.

Free cash flow surged 418.2% year-over-year, highlighting a dramatic improvement in cash generation capabilities.

The company maintains a minimal debt-to-equity ratio of 0.01, reflecting a conservative and low-risk capital structure.

Low dilution, liquidity, and credit risk flags suggest a stable financial environment with minimal immediate threats.

Revenue declined 7.0% year-over-year, signaling weakening top-line growth momentum in the most recent fiscal period.

Cash conversion ratio sits in the bottom quartile of the cohort, suggesting inefficiencies in converting earnings to cash.

Return on invested capital is merely 0.92%, indicating very low efficiency in generating returns from invested capital.

Revenue CAGR of 0.3% over four years demonstrates negligible long-term growth trajectory for the business.

Revenue TWD 83.9M, −4,7% YoY; Operating income −34,3% YoY.

• ▍Revenue TWD 83.9M, −4,7% YoY
• ▍Operating income −34,3% YoY
• ▍Net income −21,8% YoY
• ▍Free cash flow −14,5% YoY
• ▍Net margin 12.6%

Revenue TWD 85.3M, −5,7% YoY; Operating income −107,5% YoY.

• ▍Revenue TWD 85.3M, −5,7% YoY
• ▍Operating income −107,5% YoY
• ▍Net income +268,1% YoY
• ▍Free cash flow +57,6% YoY
• ▍Net margin 13.5%

Revenue TWD 351.3M, −1,1% YoY; Operating income −58,5% YoY.

• ▍Revenue TWD 351.3M, −1,1% YoY
• ▍Operating income −58,5% YoY
• ▍Net income −101,8% YoY
• ▍Free cash flow −173,9% YoY
• ▍Net margin -0.3%